Oligonucleotide CDMO Market Projected to Reach $6.73 Billion by 2029

Surge in outsourced gene-based drug manufacturing drives rapid growth in the sector.

Apr. 3, 2026 at 9:36pm

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life photograph featuring a collection of polished, geometric objects representing the various components and processes involved in oligonucleotide drug manufacturing, arranged elegantly on a clean, monochromatic background with dramatic lighting to convey the abstract concepts of the pharmaceutical industry.As the oligonucleotide CDMO market surges, specialized manufacturing capabilities and regulatory expertise become critical to the development of advanced gene-based therapies.Delray Beach Today

The global Oligonucleotide CDMO (Contract Development and Manufacturing Organization) Market is expected to grow from $2.51 billion in 2024 to $6.73 billion by 2029, at a CAGR of 21.8%. This growth reflects the increasing focus on developing and commercializing oligonucleotide-based therapies, with pharmaceutical and biotech companies relying more on CDMOs to streamline production, reduce costs, and navigate complex regulatory environments.

Why it matters

The rise of precision medicine, where therapies are tailored to specific genetic profiles, has fueled demand for oligonucleotide-based treatments. As companies accelerate innovation in this field, they are turning to specialized CDMOs that can offer scalable capabilities, advanced infrastructure, and regulatory expertise to support the transition from early-stage development to commercial production.

The details

Oligonucleotide manufacturing requires specialized expertise and stringent regulatory compliance. CDMOs provide the necessary infrastructure and capabilities, enabling companies to efficiently move from clinical to commercial-scale production. The therapeutic segment dominated the market in 2023, driven by the growing development of oligonucleotide therapies for a wide range of indications, including oncology, neurological disorders, and infectious diseases. Commercial manufacturing also accounted for the largest share, as the demand for large-scale, repeat production has surged with the increasing number of regulatory approvals for oligonucleotide-based therapies.

  • The global Oligonucleotide CDMO Market is projected to grow from $2.51 billion in 2024 to $6.73 billion by 2029.
  • The market is expected to grow at a CAGR of 21.8% during the forecast period.

The players

MarketsandMarkets™

A market research firm that has provided the projections and analysis for the global Oligonucleotide CDMO Market.

Thermo Fisher Scientific Inc., Lonza, Agilent Technologies, Inc., Kaneka Eurogentec S.A., Ajinomoto Co., Inc., Aurigene Pharmaceutical Services Ltd., Bachem, Syngene International Limited, PolyPeptide Group, WuXi AppTec, EUROAPI, Eurofins Scientific, GenScript, and Danaher Corporation

Leading players in the oligonucleotide CDMO market, focusing on capacity expansion, strategic collaborations, and technological advancements to strengthen their market positions.

Got photos? Submit your photos here. ›

The takeaway

The rapid growth of the oligonucleotide CDMO market reflects the increasing importance of outsourcing complex drug development and manufacturing processes, particularly for advanced gene-based therapies. As the industry transitions from experimental treatments to mainstream clinical use, the demand for specialized CDMOs with scalable capabilities, regulatory expertise, and advanced production facilities is expected to continue rising.